title: Severe thrombocytopenia induced by second exposure to trastuzumab can be alleviated by prolonging the interval between treatments.
authors.affiliation: Department of Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
authors.forename: Rui-chao
authors.initials: RC
authors.lastname: Zeng
authors.affiliation: Department of Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
authors.forename: Xuan-xuan
authors.initials: XX
authors.lastname: Dai
authors.affiliation: Department of Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
authors.forename: Fei-yan
authors.initials: FY
authors.lastname: Xie
authors.affiliation: Department of Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
authors.forename: En-dong
authors.initials: ED
authors.lastname: Chen
authors.affiliation: Department of Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
authors.forename: Jin-miao
authors.initials: JM
authors.lastname: Qu
authors.affiliation: Department of Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China. Electronic address: hxqoncology@163.com.
authors.forename: Xiao-qu
authors.initials: XQ
authors.lastname: Hu
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control*; D013997:Time Factors; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab
keywords: Breast carcinoma; Thrombocytopenia; Trastuzumab